Skip to main content
. Author manuscript; available in PMC: 2022 Jul 18.
Published in final edited form as: Leukemia. 2022 Jan 18;36(4):1015–1024. doi: 10.1038/s41375-021-01477-x

Figure 5. Analysis of residual tumor and CAR T cells in mouse peripheral blood.

Figure 5.

Blood was collected 46–50 days post tumor challenge and analyzed with multicolor flow cytometry. A. FACS plots depict the gating strategy used to identify CAR-T and tumor cells in mouse peripheral blood. Viable singlets were gated for CD3+ EGFR+ CAR-T cells and CD10+ tumor cells. B. FACS plots of CD3+ T cell or CD10+ tumor cells in PBS, Mock, CD19 Single CAR, BAFF-R Single CAR and CD19-BAFF-R (l) Dual CAR treated mouse blood. One mouse is displayed as representative of each cohort. C. The dot graph shows the cumulative data of CD3+ T cell or CD10+ tumor cells from five mice in each cohort. Data were analyzed by a Student’s t-test; ****P<0.0001, NS, not significant. D. Lineage analysis of tumor cells for CD19 and BAFF-R expression based off CD10 gating in PBS, Mock, BAFF-R single CAR, CD-19 single CAR, and CD19-BAFF-R(l) Dual CAR groups. E. Cumulative data of CD19 and BAFF-R expression from five mice in each cohort are presented. Data were analyzed by a Student’s t-test; ****P<0.0001, NS, not significant. F. Percentages of CAR (EGFR) T cells from CD3 gate are depicted from one representative mouse. FACS analysis plots from one representative mouse are displayed for each cohort. E. Cumulative data of CAR T cells from 5 mice per cohort are presented. Data were analyzed by a Student’s t-test; *P<0.05, NS: not statistically significant.